{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=33",
    "query": {
      "condition": "HER2-normal",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 1188,
    "total_pages": 119,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T05:22:46.469Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05966584",
      "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant or AIs) and PI3K inhibition (alpelisib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2023-07-06",
      "completion_date": "2024-08-02",
      "has_results": true,
      "last_update_posted_date": "2024-08-29",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05966584"
    },
    {
      "nct_id": "NCT07218432",
      "title": "A Study of the TheraBionic P1 Device in Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer Stage I",
        "Breast Cancer Stage II",
        "Breast Cancer Stage IIIA",
        "Hormone Receptor Positive Tumor",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TheraBionic P1 Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "22 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2026-10",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 8,
      "location_summary": "Clarkston, Michigan • Detroit, Michigan • Farmington Hills, Michigan + 5 more",
      "locations": [
        {
          "city": "Clarkston",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Flint",
          "state": "Michigan"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218432"
    },
    {
      "nct_id": "NCT01674140",
      "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "exemestane",
          "type": "DRUG"
        },
        {
          "name": "goserelin acetate",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1939,
      "start_date": "2013-09-12",
      "completion_date": "2030-01",
      "has_results": true,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 1454,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674140"
    },
    {
      "nct_id": "NCT04851613",
      "title": "Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Afuresertib",
          "type": "DRUG"
        },
        {
          "name": "Afuresertib/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laekna Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 256,
      "start_date": "2022-02-18",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 6,
      "location_summary": "Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04851613"
    },
    {
      "nct_id": "NCT02712723",
      "title": "Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qamar Khan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 121,
      "start_date": "2016-02",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 13,
      "location_summary": "Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02712723"
    },
    {
      "nct_id": "NCT05768880",
      "title": "Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Midline Glioma",
        "Recurrent CNS Tumor, Adult",
        "Recurrent, CNS Tumor, Childhood",
        "Refractory Primary Malignant Central Nervous System Neoplasm"
      ],
      "interventions": [
        {
          "name": "SC-CAR4BRAIN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "1 Year to 26 Years"
      },
      "enrollment_count": 72,
      "start_date": "2023-05-05",
      "completion_date": "2043-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05768880"
    },
    {
      "nct_id": "NCT00016276",
      "title": "Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiac Toxicity",
        "Inflammatory Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "dexrazoxane hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 396,
      "start_date": "2001-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00016276"
    },
    {
      "nct_id": "NCT04903080",
      "title": "HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ependymoma"
      ],
      "interventions": [
        {
          "name": "HER2 Specific CAR T Cell",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "1 Year to 22 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-07-27",
      "completion_date": "2033-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903080"
    },
    {
      "nct_id": "NCT05458674",
      "title": "Tucatinib+Trastuzumab+Eribulin in HER2+ MBC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Criterium, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2024-01-30",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Issaquah",
          "state": "Washington"
        },
        {
          "city": "Spokane Valley",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05458674"
    },
    {
      "nct_id": "NCT03822468",
      "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 376,
      "start_date": "2019-06-11",
      "completion_date": "2024-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-11-15T05:22:46.469Z",
      "location_count": 14,
      "location_summary": "Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03822468"
    }
  ]
}